Abstract
Objective: To determine whether 3-month GnRH analogue (GnRH-a) administration to hyperandrogenic anovulatory patients and healthy women affects glucose utilization or endogenous glucose production (EGP) in the postabsorptive state and during variable hyperglycemic-hyperinsulinemic infusions.Design: Prospective, nonrandomized study.Setting: Academic research environment.Patient(s): Twelve hyperandrogenic anovulatory patients and 11 healthy women matched by body mass index and waist to hip circumference ratio.Intervention(s): Variable hyperglycemic-hyperinsulinemic infusions replicated physiological increases in circulating glucose and insulin levels before and after 3-month GnRH-a administration.Main outcome measure(s): Glucose utilization and EGP.Result(s): In the postabsorptive state, plasma glucose and insulin levels, glucose utilization, and EGP were similar in hyperandrogenic patients and healthy women. During variable hyperglycemic-hyperinsulinemic infusions, glucose use increased and EGP decreased to similar degrees in both groups of women. Three-month GnRH-a administration to hyperandrogenic patients and healthy women did not affect plasma glucose and insulin levels, glucose utilization and EGP in the postabsorptive state, or glucose utilization and EGP during variable hyperglycemic-hyperinsulinemic infusions.Conclusion(s): Glucose use and EGP in the postabsorptive state and during variable hyperglycemic-hyperinsulinemic infusions are similar in hyperandrogenic anovulatory patients and healthy women of similar body fat distribution and are unaffected by 3-month GnRH-a administration. Copyright (C) 1999 American Society for Reproductive Medicine.
Original language | English (US) |
---|---|
Pages (from-to) | 458-466 |
Number of pages | 9 |
Journal | Fertility and Sterility |
Volume | 72 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1999 |
Externally published | Yes |
Fingerprint
Keywords
- Androgens
- Hyperandrogenic anovulation
- Insulin resistance
ASJC Scopus subject areas
- Obstetrics and Gynecology
Cite this
Insulin action during variable hyperglycemic-hyperinsulinemic infusions in hyperandrogenic anovulatory patients and healthy women. / Dumesic, Daniel A.; Abbott, David H.; Eisner, Joel R.; Nair, K Sreekumaran; Rizza, Robert A.
In: Fertility and Sterility, Vol. 72, No. 3, 09.1999, p. 458-466.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Insulin action during variable hyperglycemic-hyperinsulinemic infusions in hyperandrogenic anovulatory patients and healthy women
AU - Dumesic, Daniel A.
AU - Abbott, David H.
AU - Eisner, Joel R.
AU - Nair, K Sreekumaran
AU - Rizza, Robert A.
PY - 1999/9
Y1 - 1999/9
N2 - Objective: To determine whether 3-month GnRH analogue (GnRH-a) administration to hyperandrogenic anovulatory patients and healthy women affects glucose utilization or endogenous glucose production (EGP) in the postabsorptive state and during variable hyperglycemic-hyperinsulinemic infusions.Design: Prospective, nonrandomized study.Setting: Academic research environment.Patient(s): Twelve hyperandrogenic anovulatory patients and 11 healthy women matched by body mass index and waist to hip circumference ratio.Intervention(s): Variable hyperglycemic-hyperinsulinemic infusions replicated physiological increases in circulating glucose and insulin levels before and after 3-month GnRH-a administration.Main outcome measure(s): Glucose utilization and EGP.Result(s): In the postabsorptive state, plasma glucose and insulin levels, glucose utilization, and EGP were similar in hyperandrogenic patients and healthy women. During variable hyperglycemic-hyperinsulinemic infusions, glucose use increased and EGP decreased to similar degrees in both groups of women. Three-month GnRH-a administration to hyperandrogenic patients and healthy women did not affect plasma glucose and insulin levels, glucose utilization and EGP in the postabsorptive state, or glucose utilization and EGP during variable hyperglycemic-hyperinsulinemic infusions.Conclusion(s): Glucose use and EGP in the postabsorptive state and during variable hyperglycemic-hyperinsulinemic infusions are similar in hyperandrogenic anovulatory patients and healthy women of similar body fat distribution and are unaffected by 3-month GnRH-a administration. Copyright (C) 1999 American Society for Reproductive Medicine.
AB - Objective: To determine whether 3-month GnRH analogue (GnRH-a) administration to hyperandrogenic anovulatory patients and healthy women affects glucose utilization or endogenous glucose production (EGP) in the postabsorptive state and during variable hyperglycemic-hyperinsulinemic infusions.Design: Prospective, nonrandomized study.Setting: Academic research environment.Patient(s): Twelve hyperandrogenic anovulatory patients and 11 healthy women matched by body mass index and waist to hip circumference ratio.Intervention(s): Variable hyperglycemic-hyperinsulinemic infusions replicated physiological increases in circulating glucose and insulin levels before and after 3-month GnRH-a administration.Main outcome measure(s): Glucose utilization and EGP.Result(s): In the postabsorptive state, plasma glucose and insulin levels, glucose utilization, and EGP were similar in hyperandrogenic patients and healthy women. During variable hyperglycemic-hyperinsulinemic infusions, glucose use increased and EGP decreased to similar degrees in both groups of women. Three-month GnRH-a administration to hyperandrogenic patients and healthy women did not affect plasma glucose and insulin levels, glucose utilization and EGP in the postabsorptive state, or glucose utilization and EGP during variable hyperglycemic-hyperinsulinemic infusions.Conclusion(s): Glucose use and EGP in the postabsorptive state and during variable hyperglycemic-hyperinsulinemic infusions are similar in hyperandrogenic anovulatory patients and healthy women of similar body fat distribution and are unaffected by 3-month GnRH-a administration. Copyright (C) 1999 American Society for Reproductive Medicine.
KW - Androgens
KW - Hyperandrogenic anovulation
KW - Insulin resistance
UR - http://www.scopus.com/inward/record.url?scp=0033198731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033198731&partnerID=8YFLogxK
U2 - 10.1016/S0015-0282(99)00265-4
DO - 10.1016/S0015-0282(99)00265-4
M3 - Article
C2 - 10519617
AN - SCOPUS:0033198731
VL - 72
SP - 458
EP - 466
JO - Fertility and Sterility
JF - Fertility and Sterility
SN - 0015-0282
IS - 3
ER -